All the hard talk will be deleted — but only if Michelle and the...

All the hard talk will be deleted — but only if Michelle and the team deliver tangible results that offer real potential for shareholder gains.

Yes, biotech takes time — but let’s be honest about what happened:
Michelle and her team went silent, either due to complacency or blind reliance on C14 delivering something meaningful within an assumed timeframe. During a period of market interest and momentum, they failed to act — not even taking the basic step of raising funds through the exercise of in-the-money options.

At this point, it should be a billion-dollar research question how Michelle and her team actually spend their office hours — and how they justify their executive compensation while doing so little to protect or grow shareholder value.

By the time they finally responded, they rushed into a capital raise at rock-bottom prices — effectively wiping out shareholder value like it was toilet paper. The result? Long-term investors got diluted, while management conveniently topped up their own holdings using the funds raised from those same shareholders.

And now? We're back to silence. No timelines. No updates. No accountability. Nothing but waiting — again.